PharmaRoth Labs, Inc. (ROTH)

[sweetlou]

Metformin, arguably the first line oral agent for non insulin dependent diabetes, has a 30 percent rate of GI side effects, some of which subside with time, but 5 percent discontinue do to persistent intolerance. On top of that it is contraindicated in renal disease, congestive heart failure, and acidosis (due to an increased risk of lactic acidosis which is fatal in 50%)
Contrast that to Sucanon as a first line agent that outperformed Glyburide in a double blind placebo controlled trial, with weight loss (vs usual weight gain), and no observed side effects common to oral diabetes agents and there is a great opportunity for this product based on the science. I await with interest the study results from ABC hospital in Mexico City to obtain further information supporting the previously available excellent Sucanon study results.